For the 2007 third quarter, Schering-Plough reported net income available to common shareholders of $713 million or 45 cents per common share on a GAAP basis. Excluding acquisition-related items and an up front R&D payment, earnings per share for the 2007 third quarter would have been 28 cents. For the same period in 2006 the company reported net income of $287 million or 19 cents per common share on a GAAP basis.
Strong sales
Net sales for the 2007 third quarter rose nine percent on a GAAP basis and 12 percent on an adjusted basis versus the 2006 period. GAAP net sales for the 2007 third quarter totaled $2.8 billion; adjusted net sales, which includes an assumed 50 percent of global cholesterol net sales from its joint venture with Merck & Co.(human health), would have totaled $3.5 billion. This compares with $3.1 billion for a similar adjusted basis for the 2006 third quarter.
Consumer health care sales were $273 million in the 2007 third quarter, up five percent versus the 2006 period. Animal health sales increased 8 percent to $248 million, reflecting solid growth internationally, led by the poultry, companion animal, aquaculture and swine product lines, coupled with a positive impact from foreign currency exchange rates. The growth in international markets was tempered by a decline in the United States.
Research and development spending for the 2007 third quarter also increased to $669 million, compared to $536 million in the third quarter of last year.
Aqusition part of long-term plan
The aquisition of Organon BioSciences from Akzo Nobel, which includes animal health company Intervet, falls in line with SP's long-term strategy to continue to grow the top line, exercise financial discipline and expand it's R&D pipeline. The company beleives this formular will continue to deliver strong results.
"Our focus on building R&D excellence is beginning to bear fruit and with the upcoming acquisition of Organon BioSciences, we will have a total of 12 significant projects in Phase III," said Fred Hassan, company chairman and CEO.
"This, combined with relatively long exclusivity of our product portfolio, puts Schering-Plough in a substantially stronger position in terms of its late-stage pipeline and portfolio than only four years ago," he added.
The deal has already gained European Commission approval and most of the financing plan, involving nearly $9 billion secured through a mix of equity and debt of varying maturities, has been finalised. The customary consultative process with the OBS Works Council in the Netherlands is also complete.
Strong sales
Net sales for the 2007 third quarter rose nine percent on a GAAP basis and 12 percent on an adjusted basis versus the 2006 period. GAAP net sales for the 2007 third quarter totaled $2.8 billion; adjusted net sales, which includes an assumed 50 percent of global cholesterol net sales from its joint venture with Merck & Co.(human health), would have totaled $3.5 billion. This compares with $3.1 billion for a similar adjusted basis for the 2006 third quarter.
Consumer health care sales were $273 million in the 2007 third quarter, up five percent versus the 2006 period. Animal health sales increased 8 percent to $248 million, reflecting solid growth internationally, led by the poultry, companion animal, aquaculture and swine product lines, coupled with a positive impact from foreign currency exchange rates. The growth in international markets was tempered by a decline in the United States.
Research and development spending for the 2007 third quarter also increased to $669 million, compared to $536 million in the third quarter of last year.
Aqusition part of long-term plan
The aquisition of Organon BioSciences from Akzo Nobel, which includes animal health company Intervet, falls in line with SP's long-term strategy to continue to grow the top line, exercise financial discipline and expand it's R&D pipeline. The company beleives this formular will continue to deliver strong results.
"Our focus on building R&D excellence is beginning to bear fruit and with the upcoming acquisition of Organon BioSciences, we will have a total of 12 significant projects in Phase III," said Fred Hassan, company chairman and CEO.
"This, combined with relatively long exclusivity of our product portfolio, puts Schering-Plough in a substantially stronger position in terms of its late-stage pipeline and portfolio than only four years ago," he added.
The deal has already gained European Commission approval and most of the financing plan, involving nearly $9 billion secured through a mix of equity and debt of varying maturities, has been finalised. The customary consultative process with the OBS Works Council in the Netherlands is also complete.
Further Reading
- Go to a previous news item on this story by clicking here. |